국가: 오스트레일리아
언어: 영어
출처: Department of Health (Therapeutic Goods Administration)
milrinone, Quantity: 10 mg
Baxter Healthcare Pty Ltd
Milrinone
Injection, concentrated
Excipient Ingredients: glucose; water for injections; sodium hydroxide; lactic acid
Intravenous
10 mL ampoules, 10 ampoules per pack, 10 mL ampoules, 5 ampoules per pack
(S4) Prescription Only Medicine
MILRINONE-BAXTER is indicated for the short term (48 hours) intravenous therapy of severe congestive heart failure patients in intensive care and coronary care units not responding to other therapy (e.g. digoxin, diuretics, vasodilators, including ACE inhibitors). The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. ,MILRINONE-BAXTER is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.
Visual Identification: Sterile, clear, colourless to pale yellow solution, practically free from visible particles; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2015-04-17
MILRINONE-CLARIS _Milrinone lactate, Concentrated Solution for injection _ _ _ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions people ask about Milrinone-Claris. It does not contain all the information that is known about Milrinone-Claris. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor will have weighed the risks of you taking Milrinone-Claris against the benefits they expect it will have for you. This medicine is likely to be used while you are at the clinic or in hospital. If possible, please read this leaflet carefully before this medicine is given to you. In some cases this leaflet may be given to you after the medicine has been used. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT MILRINONE-CLARIS IS USED FOR Milrinone-Claris is used for the short term treatment of severe congestive heart failure. This is a condition where the heart fails to pump enough blood around the body. The symptoms of this condition include weakness, breathlessness, fluid build-up in the tissues and a blue discolouration of the skin. Milrinone-Claris also helps to maintain the output of blood from the heart in patients following heart surgery. Milrinone-Claris helps improve the efficiency with which your heart pumps blood around your body. Milrinone-Claris works by increasing the force by which your heart muscles work and opening up your blood vessels to allow blood to flow more freely. BEFORE YOU ARE GIVEN IT _WHEN YOU MUST NOT BE GIVEN IT: _ YOU SHOULD NOT USE MILRINONE-CLARIS IF YOU ARE ALLERGIC TO MILRINONE, SIMILAR MEDICINES, OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. The symptoms of an allergic reaction may include a rash, asthma attack or hay fever. YOU SHOULD NOT USE MILRINONE-CLARIS IF YOU HAVE CERTAIN SEVERE PROBLEMS (OBSTRUCTIVE AORTIC OR PULMONARY VALVULAR DISEASE). MILRINONE-CLARI 전체 문서 읽기
Milrinone-Baxter (Milrinone lactate) Version 1.0 1 of 11 AUSTRALIAN PRODUCT INFORMATION – MILRINONE- BAXTER (MILRINONE LACTATE) CONCENTRATED SOLUTION FOR INFUSION 1 NAME OF THE MEDICINE Milrinone (as lactate) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Milrinone-Baxter is a sterile, clear, colourless to pale yellow aqueous solution, practically free from visible particles, containing milrinone lactate equivalent to milrinone 10 mg/10 mL. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Concentrated Solution for Infusion 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Milrinone-Baxter is indicated for the short term (48 hours) intravenous therapy of severe congestive heart failure patients in intensive care and coronary care units not responding to other therapy (e.g. digoxin, diuretics, vasodilators, including ACE inhibitors). The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. Milrinone-Baxter is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump. 4.2 DOSE AND METHOD OF ADMINISTRATION Milrinone-Baxter requires dilution prior to administration to patients intravenously. Milrinone-Baxter should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines: LOADING DOSE 50 µg/kg administer slowly over 10 minutes MAINTENANCE DOSE INFUSION RATE TOTAL DAILY DOSE (24 HOURS) MINIMUM 0.375 µg/kg/min 0.60 mg/kg STANDARD 0.50 µg/kg/min 0.77 mg/kg MAXIMUM 0.75 µg/kg/min 1.13 mg/kg Note: Administer as a continuous intravenous infusion. Milrinone-Baxter (Milrinone lactate) Version 1.0 2 of 11 The infusion rate should be adjusted according to haemodynamic and clinical response. Patients should be closely monitored. Most patients show an improvement in haemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure. Note: See "Dosage Adjustment 전체 문서 읽기